Lupin Limited

NSE: LUPIN

Pharma Pharmaceuticals

₹2,281.4

+1.52%EOD · 11 Jun

Lupin Limited is a listed Pharmaceuticals company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹1.03 L Cr

52W Range

₹2494 / ₹1837

Volume

721K

1Y Return

+16.3%

P/E Ratio

19.5

P/B Ratio

4.6

ROE

26.9%

Debt / Equity

29.39

Peers in Pharma

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Lupin Limited(this stock)	₹2,281.4	₹1.03 L Cr	19.5	4.6	26.9%	0.53%
Sun Pharmaceutical Industries LimitedSUNPHARMA	₹1,796.6	₹4.29 L Cr	37.3	5.1	14.7%	0.93%
Cipla LimitedCIPLA	₹1,386	₹1.11 L Cr	29.2	3.4	11.7%	0.93%
Dr. Reddy's Laboratories LimitedDRREDDY	₹1,277	₹1.06 L Cr	24.9	2.8	11.8%	0.63%

Technical Indicators

Full analysis · objective math, not advice

Returns

+1.5%

+0.6%

+1.3%

-0.7%

+8.3%

+16.3%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

55 Neutral

Trend Template

5/7moderate

Moving Averages (price vs MA)

20-DMA

₹2269

above

50-DMA

₹2287

below

150-DMA

₹2225

above

200-DMA

₹2164

above

From 52W High

-8.5%

From 52W Low

+24.2%

Support (20D)

₹2220

Resistance (20D)

₹2310

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+6.5% CAGR

Up 8 of last 11 years

Earnings Quality

Mostly cash-backed

OCF / Net Profit = 0.87x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.